See the DrugPatentWatch profile for fidaxomicin
Who owns the patent(s) for fidaxomicin, and what are they for?
Fidaxomicin is an antibiotic marketed for treating Clostridioides difficile infections. Patent activity around fidaxomicin has historically covered core chemistry and specific formulations, along with related uses in treating C. difficile. The exact assignee(s) and claim scope depend on the particular patent family and jurisdiction, because different filings can cover different aspects (drug substance, compositions, and methods of treatment).
When do fidaxomicin patents expire (U.S. and Europe)?
Patent expiry timing varies by country because it depends on filing dates, patent term adjustments, and any supplementary protection such as EU SPC (where applicable). Fidaxomicin’s market exclusivity in a given region is usually driven by the later-expiring elements in a family (for example, a formulation or method-of-use patent, plus any regulatory exclusivity layered on top).
What counts as “patent” versus “exclusivity” for fidaxomicin?
People often use “patent” loosely when they actually mean one of several protections:
- Patent term protection (from issued patents).
- Regulatory exclusivity tied to approvals and data protection.
- In some regions, supplementary protection certificates (SPCs) that extend patent-like protection for certain medicines.
Because these can start and end on different timelines, generic or competitor launch dates may follow the last protection expiring rather than the first patent listed in a news story.
Can generic or biosimilar fidaxomicin launch before the main patents expire?
Fidaxomicin is a small-molecule drug, so “biosimilar” is not the right category; the relevant question is generic entry. A generic can sometimes be approved before all patents expire if it follows the regulatory pathway for abbreviated approval, but actual commercial marketing usually depends on whether patents are still enforceable and whether a “skinny label” or other workaround is possible. If patent litigation is ongoing, launch dates often shift until the courts or settlements resolve infringement questions.
Are companies challenging fidaxomicin patents?
Patent disputes are common for established antibiotics where generics seek market entry. The ability to launch depends on whether challengers can invalidate specific claims or avoid infringement through different dosing regimens, formulations, or labeling. Any challenge is typically tied to a specific patent list and claim interpretation in the relevant jurisdiction.
What kinds of fidaxomicin patents exist (substance vs. formulation vs. method)?
Fidaxomicin patent families often split into:
- Drug substance (the core chemical compound and related variants).
- Drug product/composition (formulations, dosage forms, or stability-related aspects).
- Methods of treatment (specific therapeutic uses, dosing schedules, or patient populations).
When people ask about “patent fidaxomicin,” they often want to know which of these is controlling in their country.
How do you look up the exact fidaxomicin patents you mean?
“Patent fidaxomicin” can refer to multiple patent families over time. To get a precise answer (including exact numbers and expiry dates), you typically need at least:
- Country/region (U.S., EP, UK, etc.).
- Whether you care about drug substance, formulation, or method claims.
- The marketing authorization holder (who holds the approved product rights in that region).
Then you can map patents listed for that product to their claim categories and term end dates.
What I need to give you exact patent numbers and expiry dates
Tell me:
1) Which country/region (e.g., U.S., EU/EP, UK), and
2) Whether you mean the original fidaxomicin (Dificid) product, or a specific formulation/trial,
and I’ll return the specific patent(s) and the earliest likely expiry date for that jurisdiction.
Sources
No sources were provided in your prompt, so I can’t cite specific fidaxomicin patent numbers or expiry dates yet.